MGI Tech Co. issued a statement detailing the use of its technology in improving the rates of genomic sequencing in South Africa.
Genomic technology is being used in South Africa to research and identify natural controls for HIV infections. MGI Tech Co., announced its sequencing tools are being utilized at the South African Medical Research Council (SAMRC) and the University of KwaZulu-Natal. HIV continues to be a significant problem in the region, which has the largest number of people living with HIV.
However, MGI states that the African human genome is the least sequenced among human genomes. This presents a significant problem, as proper genetic sequencing allows experts to create more targeted treatment programs and create more effective treatments for HIV.
Rizwana Mia is the co-founder of the SAMRC Genomics Center and the senior program manager of precision medicine at the SAMRC. In a press release, Mia said, “The HIV Host Genome project was started at the same time as we launched SAMRC's African Genomics Centre in Cape Town with the support from MGI. The partnership saw MGI putting down a high-throughput sequencing workflow, and assisted us with the specialized scaled infrastructure design in our lab. This was at a time when there was no real infrastructure for large-scale next generation sequencing in Africa."
Mia continued, “More importantly, by moving our laboratory workflow to scale, we are hoping to develop genomic research to address this quadruple burden of disease that South Africa faces. Our project looks at a unique cohort of patients that have the ability to control the HIV virus to ascertain how disease progresses and the host-directed mechanisms for innate immune control. In addition, we included family sets to help us better understand the relationship between pediatric non-progressors and their parents who are also HIV positive, to uncover and genetic differences that may contribute to host immune control of HIV."
Dr. Veron Ramsuran, principal investigator of the HIV Host Genome project also discussed the importance of genomic sequencing in the region, saying, “We've identified new genes and polymorphism that are playing a role with HIV disease through new data generated from Whole Genome Sequencing. Traditionally, there is a list of mutations or genes that are known to associate with HIV, yet they are largely based on studies on Caucasian populations. Our HIV research is adding to the general pool of knowledge pertaining to individuals of African descent, which will thereby inform new treatment and new vaccine opportunities."
Ramsuran continued, “What's important is also understanding how drugs interact with the individual. We've found in the past that certain polymorphism is associated with drug metabolism in genes. Building on this understanding of drugs in combination with the genetics of the individual, we can develop prediction tools to inform clinicians on drug type or dosage depending on the presence of the polymorphism to facilitate a more rapid metabolism of the drug."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.